Oral Tumoractivated Chemotherapy: A New Effective and Convenient Treatment in Oncology

Satellite Symposium held at the 23rd ESMO Congress
Athens, Greece, November 6, 1998

Guest Editor
Stan Kaye, Glasgow, UK
The satellite symposium and the publication of this supplement were supported by an educational grant from F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Contents

1 Oral Tumoractivated™ Chemotherapy – An Introduction
   Kaye, S.B. (Glasgow)

2 Fluoropyrimidines: A Critical Evaluation
   Pazdur, R. (Houston, Tex.)

9 Rational Design of New Tumoractivated™ Cytotoxic Agents
   Verweij, J. (Rotterdam)

16 Xeloda® in the Treatment of Metastatic Breast Cancer
   Blum, J.L. (Dallas, Tex.)

21 Optimizing Chemotherapy for Patients with Advanced Breast Cancer
   Marty, M.; Espie, M.; Cottu, P.H.; Cuvier, C.; Lerebours, F. (Paris)

27 Potential of Xeloda® in Colorectal Cancer and Other Solid Tumors
   Cassidy, J. (Aberdeen)